Zygomycosis (Mucormycosis) - Causes, Treatment & When to See a Doctor

What is Zygomycosis (Mucormycosis)?

Zygomycosis, more commonly referred to as mucormycosis, is a rare but serious fungal infection caused by a group of molds called Mucorales. These molds are found naturally in soil, decaying organic matter, compost piles, and even in the air we breathe. In most healthy individuals the immune system quickly clears the spores, but in people with weakened immunity the fungi can invade blood vessels and tissue, leading to rapid tissue necrosis.

The infection can affect many body sites, the most frequent being:

• Sinus and nasal passages (rhino‑orbital‑cerebral mucormycosis)
• Lungs (pulmonary mucormycosis)
• Skin and soft tissue (cutaneous mucormycosis)
• Gastro‑intestinal tract
• Disseminated disease that spreads to multiple organs

Because mucormycosis progresses quickly, early recognition and prompt treatment are essential to improve survival, which ranges from 30‑80% depending on the site and patient’s health status ^[1].

Common Causes

The fungi that cause mucormycosis are opportunistic—they take advantage of certain conditions that impair the body’s normal defenses. The following list includes the most frequent pre‑disposing factors:

• Uncontrolled Diabetes Mellitus – especially with ketoacidosis.
• Hematologic malignancies such as acute leukemia or lymphoma.
• Solid‑organ or stem‑cell transplantation with immunosuppressive therapy.
• Prolonged neutropenia (low neutrophil count) from chemotherapy.
• Corticosteroid therapy – high‑dose or chronic use.
• Iron overload or treatment with deferoxamine (a chelator that paradoxically feeds the fungus).
• Severe burns or traumatic skin injuries that expose tissue to contaminated material.
• Granulomatous diseases (e.g., sarcoidosis) requiring long‑term steroids.
• COVID‑19 infection – especially in patients receiving steroids or with diabetes (the “COVID‑associated mucormycosis” outbreak reported in 2020‑2022).
• Extensive use of broad‑spectrum antibiotics that disrupt normal bacterial flora.

Environmental exposure alone rarely causes disease; it is the combination of a vulnerable host and a high inoculum of spores that leads to infection.

Associated Symptoms

Symptoms vary according to the organ involved. Below are the typical clinical pictures for the major forms:

Rhino‑orbital‑cerebral (sinus & eye) form

• Facial pain, swelling, or numbness
• Black, necrotic tissue inside the nasal cavity or palate
• Fever
• Vision changes, double vision, or loss of eye movement
• Headache and possible confusion if the brain is involved

Pulmonary form

• Fever, chills, and night sweats
• Cough (sometimes with blood‑tinged sputum)
• Chest pain or shortness of breath
• Weight loss

Cutaneous form

• Redness, swelling, and pain at a wound site
• Rapid progression to black eschar (dead tissue)
• Fever if infection spreads

Gastro‑intestinal form

• Abdominal pain, nausea, vomiting
• Gastrointestinal bleeding
• Peritonitis in severe cases

Disseminated disease

• Multiorgan failure signs – fever, hypotension, altered mental status
• Skin lesions at distant sites (suggesting spread through blood)

Because the infection can destroy blood vessels, tissue necrosis may appear suddenly and progress over hours to days.

When to See a Doctor

Any of the following situations should prompt an immediate medical evaluation:

• Fever combined with facial swelling, sinus pain, or black nasal discharge, especially in a person with diabetes or on steroids.
• Cough with bloody sputum, chest pain, or worsening shortness of breath in an immunocompromised patient.
• Rapidly spreading skin discoloration or ulcer that turns black.
• Sudden vision loss, eye pain, or double vision.
• Severe abdominal pain with vomiting or rectal bleeding in a high‑risk individual.
• Any new, unexplained neurological symptoms (headache, confusion, seizures) after sinus or facial infection.

Prompt evaluation can mean the difference between a curable infection and life‑threatening disease.

Diagnosis

Diagnosing mucormycosis requires a combination of clinical suspicion and laboratory testing.

1. Imaging

• CT scan of the sinuses, chest, or abdomen to identify tissue invasion, bone destruction, or cavitary lung lesions.
• MRI for detailed evaluation of orbital or central nervous system involvement.

2. Direct Microscopy & Histopathology

• Biopsy of affected tissue examined with potassium hydroxide (KOH) prep or calcofluor staining shows broad, ribbon‑like, non‑septate hyphae that branch at right angles.
• Special stains (Gomori methenamine silver, Periodic acid‑Schiff) highlight fungal elements.

3. Culture

• Fungal cultures on Sabouraud dextrose agar can grow Mucorales, but they are often negative because the organisms are fragile. A negative culture does not rule out infection.

4. Molecular Techniques

• Polymerase chain reaction (PCR) assays on tissue or blood can detect fungal DNA more rapidly.

5. Laboratory Markers

• Elevated serum ferritin and iron levels may support the diagnosis in diabetics or patients on deferoxamine.
• Routine blood counts to assess neutropenia.

Because the disease progresses quickly, clinicians often start empirical antifungal therapy when mucormycosis is strongly suspected, even before definitive results are available.

Treatment Options

Treatment is multimodal—combining medical therapy, surgical intervention, and management of underlying risk factors.

1. Antifungal Medications

• Liposomal Amphotericin B – the drug of choice; dose 5–10 mg/kg IV daily. Liposomal formulation reduces kidney toxicity compared with conventional amphotericin B.
• Isavuconazole or Posaconazole – oral or IV agents used as step‑down therapy after initial amphotericin B or when amphotericin is contraindicated.
• Treatment duration is usually 6–12 weeks, guided by radiologic and clinical response.

2. Surgical Debridement

• Prompt removal of necrotic tissue is critical; surgery may involve sinus debridement, orbital exenteration, lung resection, or extensive skin excision.
• Repeated debridements are often necessary because the fungus spreads along blood vessels.

3. Control of Underlying Conditions

• Rapid correction of diabetic ketoacidosis with insulin and fluid replacement.
• Reduction or discontinuation of immunosuppressive drugs when feasible.
• Discontinuation of deferoxamine; consider alternative iron chelation (e.g., deferasirox) if needed.
• Optimization of neutrophil counts – use of granulocyte-colony stimulating factor (G‑CSF) in neutropenic patients.

4. Adjunctive Therapies (Emerging)

• Hyperbaric oxygen therapy (HBOT) – may improve oxygenation of infected tissue and enhance neutrophil function, though evidence is limited.
• Iron chelation with deferasirox – experimental; not routinely recommended.

5. Home Care & Supportive Measures

• Maintain strict glucose control; monitor blood sugars at least four times daily if diabetic.
• Stay hydrated and follow up with wound care instructions if surgery was performed.
• Adhere to antifungal medication schedule; report any side effects (renal dysfunction, liver enzyme elevation) promptly.

Prevention Tips

While it is impossible to eliminate exposure to environmental molds, several strategies can lower the risk of mucormycosis, especially for high‑risk individuals.

• Control blood sugar – keep HbA1c < 7 % if possible; treat ketoacidosis immediately.
• Avoid unnecessary corticosteroids – use the lowest effective dose for the shortest duration.
• Maintain good wound hygiene – clean cuts promptly, keep dressings dry, and avoid exposure to soil or dusty environments.
• Use protective equipment when handling compost, mulch, or decaying vegetation (gloves, masks).
• Limit exposure in hospital settings – HEPA filtration in high‑risk wards, regular cleaning of ventilation systems.
• Monitor iron status – avoid deferoxamine unless absolutely necessary.
• Vaccinate against COVID‑19 and follow public‑health guidance to reduce severe COVID cases that often require steroids.
• Early treatment of sinus infections; do not ignore persistent nasal congestion or facial pain.

Emergency Warning Signs

---

References:

1. Mayo Clinic. “Mucormycosis (black fungus)”. Updated 2023. https://www.mayoclinic.org
2. Cleveland Clinic. “Mucormycosis (Black Fungus)”. 2022. https://my.clevelandclinic.org
3. Centers for Disease Control and Prevention (CDC). “Mucormycosis”. 2023. https://www.cdc.gov
4. World Health Organization. “Guidelines for the Diagnosis and Management of Invasive Fungal Diseases”. 2021.
5. Rodrigues CF, et al. “Mucormycosis: epidemiology and clinical manifestations”. *Lancet Infect Dis*. 2020;20(7):e223‑e234.